Table 5.

CMV and EBV viremia in sero(+) non-DES patients who received valganciclovir (VGCV-LD) versus acyclovir prophylaxis (ACV-anti-IL-2R).

Patients	Number of patients (%)
	w/CMV-PCR > 30 copies/PCR
CMV sero(+) non-DES
VGCV-LD (n = 176)	31 (17.6)
ACV-anti-IL-2R (n = 175)	26 (14.9)
VGCV-LD-ATZ (n = 25)	7 (28.0)
VGCV-LD-ATG (n = 151)	24 (15.9)
	w/EBV-PCR > 30 copies/PCR
EBV sero(+) non-DES
VGCV-LD (n = 200)	22 (11.0)
ACV-anti-IL-2R (n = 215)	6 (2.8)∗
VGCV-LD-ATZ (n = 39)	2 (5.1)
VGCV-LD-ATG (n = 161)	20 (12.4)

VGCV: valganciclovir; ACV: acyclovir.

LD: lymphocyte depletion; anti-IL-2R: anti-IL-2 receptor.

ATZ: alemtuzumab; ATG: anti-thymocyte globulin.

 ^∗p < 0.001 versus VGCV-LD by Fisher's exact test.